Alkermes To Acquire Rodin Therapeutics

Biopharmaceutical company Alkermes plc (ALKS) and Rodin Therapeutics, Inc. announced that Alkermes will acquire privately-held biopharmaceutical company Rodin, which is focused on developing novel, small molecule therapeutics for synaptopathies.

This transaction builds on Alkermes' experience and expands its Presence in central nervous system (CNS) diseases to a wide range of neurodegenerative diseases through epigenetic control of synaptogenesis.